UCIVIDY Trademark

Trademark Overview


On Tuesday, March 28, 2023, a trademark application was filed for UCIVIDY with the United States Patent and Trademark Office. The USPTO has given the UCIVIDY trademark a serial number of 97860535. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, July 15, 2024. This trademark is owned by Athira Pharma, Inc.. The UCIVIDY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, pharmaceutical preparations and pharmaceutical agents; pharmaceuticals in the nature of small molecule chemical compounds; pharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Scleros...
ucividy

General Information


Serial Number97860535
Word MarkUCIVIDY
Filing DateTuesday, March 28, 2023
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateMonday, July 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceuticals, pharmaceutical preparations and pharmaceutical agents; pharmaceuticals in the nature of small molecule chemical compounds; pharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 4, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAthira Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBothell, WA 98011

Trademark Events


Event DateEvent Description
Friday, March 31, 2023NEW APPLICATION ENTERED
Tuesday, April 4, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 21, 2023ASSIGNED TO EXAMINER
Thursday, January 18, 2024NON-FINAL ACTION WRITTEN
Thursday, January 18, 2024NON-FINAL ACTION E-MAILED
Thursday, January 18, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 26, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, January 26, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, July 15, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 16, 2024ASSIGNED TO EXAMINER